Evidence map›Paper›PMID 39286015›Full record

ArticleFrontiers in oncology2024

Clinicopathological and molecular differences between stage IV screen-detected and interval colorectal cancers in the Flemish screening program.

Isabelle Neefs, Thuy Ngan Tran, Allegra Ferrari, Sharon Janssens, Koen Van Herck, Ken Op de Beeck, Guy Van Camp, Marc Peeters, Erik Fransen, Sarah Hoeck and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Isabelle NeefsCenter of Medical Genetics, University of Antwerp and Antwerp University Hospital (UZA), Edegem, Belgium.
Thuy Ngan TranResearch group on Social Epidemiology and Health Policy, Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.
Allegra FerrariResearch group on Social Epidemiology and Health Policy, Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.
Sharon JanssensBelgian Cancer Registry, Brussels, Belgium.
Koen Van HerckBelgian Cancer Registry, Brussels, Belgium.
Ken Op de BeeckCenter of Medical Genetics, University of Antwerp and Antwerp University Hospital (UZA), Edegem, Belgium.
Guy Van CampCenter of Medical Genetics, University of Antwerp and Antwerp University Hospital (UZA), Edegem, Belgium.
Marc PeetersCenter of Medical Genetics, University of Antwerp and Antwerp University Hospital (UZA), Edegem, Belgium.
Erik FransenCenter of Medical Genetics, University of Antwerp and Antwerp University Hospital (UZA), Edegem, Belgium.
Sarah HoeckResearch group on Social Epidemiology and Health Policy, Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.
Guido Van HalResearch group on Social Epidemiology and Health Policy, Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Interval cancer (IC) is an important quality indicator in colorectal cancer (CRC) screening. Previously, we found that fecal immunochemical test (FIT) ICs are more common in women, older age, right-sided tumors, and advanced stage. Here, we extended our existing stage IV patient cohort with clinicopathological and molecular characteristics, to identify factors associated with FIT-IC. Methods: Logistic regression models were fit to identify variables associated with the odds of having a stage IV FIT-IC. Multivariate models were corrected for gender, age, and location. Results: A total of 292 screen-detected (SD) CRCs and 215 FIT-IC CRCs were included. FIT-IC CRC had 5 fold higher odds to be a neuroendocrine (NET) tumor and 2.5 fold higher odds to have lymphovascular invasion. Interestingly, some variables lost significance upon accounting for location. Thus, tumor location is a critical covariate that should always be included when evaluating factors related to FIT-IC. Conclusions: We identified NETs and lymphovascular invasion as factors associated with increased odds of having a stage IV FIT-IC. Moreover, we highlight the importance of tumor location as a covariate in evaluating FIT-IC related factors. More research across all stages is needed to clarify how these insights might help to optimize the Flemish CRC screening program.

Indexed as

clinicopathological differencescolorectal cancerinterval cancermolecular alterationsscreening

Identifiers

PMID39286015
PMCPMC11402608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.